Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Mepsevii Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C17942-A

    Mepsevii (vestronidase alfa-vjbk) for Mucopolysaccharidosis VII

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C17942-A alerts

    Get alerted when Policy C17942-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for intravenous Mepsevii in pediatric and adult members with Mucopolysaccharidosis VII, requiring diagnostic confirmation, qualifying disease manifestations, baseline assessments, qualified prescribing, and response or stability for reauthorization.

    Policy Summary
    PayerMolina Healthcare
    PolicyMepsevii (vestronidase alfa-vjbk) for Mucopolysaccharidosis VII
    Policy CodePolicy C17942-A
    Change TypeAnnual review — no material clinical or coverage changes
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization documentation confirming MPS VII, confirmatory testing, qualifying symptoms, baseline assessments, and qualified specialist prescribing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5 monthsMinimum age for coverage
    4 mg/kg q2wMepsevii dose
    12 monthsInitial authorization
    12 monthsContinuation authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J3397HCPCS code
    60 minutesPost-infusion observation

    Coverage Criteria

    Initial Therapy

    Covered when all initial therapy criteria are met:

    Initial therapy

    • Diagnosis: Member has a documented diagnosis of Mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome.
    • Diagnostic confirmation: Diagnosis is confirmed by an enzyme activity assay demonstrating beta-glucuronidase (GUSB) deficiency OR genetic testing demonstrating a mutation of chromosome 7q21.11.

      For newborn or sibling screening, elevated GAGs and two mutations consistent with MPS VII are appropriate; some members may have GAGs elevated only to 2 times the upper limit of normal.

    • Qualifying disease manifestation: Member has at least one of the following symptoms consistent with MPS VII: enlarged liver and spleen, joint limitations, airway obstruction, or pulmonary dysfunction.At least 1 symptom
    • Baseline assessments

      • Urinary GAG: Documented baseline urinary glycosaminoglycan (uGAG).
      • Age-appropriate assessment: For members 6 years or older: 6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC); for members younger than 6 years: upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, and/or 6-minute walk test.

        The applicable assessment must be documented at baseline.

    • Qualified prescriber: Treatment is prescribed by, or in consultation with, a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, physician specializing in lysosomal storage disorders, or physician experienced in managing mucopolysaccharidoses (MPS).

      If prescribed in consultation, consultation notes must be submitted with the initial request.

    Continuation Therapy

    Continuation therapy is covered when all continuation criteria are met:

    Continuation therapy

    • Positive response or disease stability

      • Decreased urinary GAG: Urinary GAG levels have decreased compared with the pretreatment baseline.
      • Age-appropriate response or stability measure: For members 6 years or older: 6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC); for members younger than 6 years: decreased hepatosplenomegaly, improvement in upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, and/or 6-minute walk test.
    • Tolerability: The prescriber attests to, or the clinical reviewer has found, no evidence of intolerable adverse effects or drug toxicity, including anaphylaxis or severe allergic reactions.

    Mepsevii is indicated for pediatric and adult patients with Mucopolysaccharidosis VII (MPS VII, Sly syndrome). The effect of Mepsevii on central nervous system manifestations of MPS VII has not been determined. Uses other than the FDA-approved MPS VII indication are considered experimental/investigational and follow Molina’s Off-Label policy.

    Coding and Clinical Parameters

    HCPCSHCPCS
    J3397Injection, vestronidase alfa-vjbk, 1 mg
    Minimum age
    Minimum age5 months of age and older
    Applies toMembers requesting Mepsevii coverage
    Authorization contextInitial authorization requires the member to be at least 5 months old
    Baseline urinary glycosaminoglycan
    Required measureUrinary glycosaminoglycan (uGAG)
    TimingBaseline, before therapy
    DocumentationBaseline uGAG must be documented with the coverage request

    Authorization and Provider Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial Mepsevii requests. Submit documentation establishing that the member is at least 5 months of age and meets the MPS VII indication and baseline requirements.

    • Documented diagnosis of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).
    • Confirm the diagnosis by enzyme activity assay showing beta-glucuronidase (GUSB) deficiency or genetic testing showing a mutation of chromosome 7q21.11. For newborn or sibling screening, elevated glycosaminoglycans (GAGs) at 2 times the upper limit of normal and two mutations consistent with MPS VII may support the diagnosis.
    • Document at least one consistent symptom: enlarged liver and spleen, joint limitations, airway obstruction, or pulmonary dysfunction.
    • Submit baseline urinary glycosaminoglycan (uGAG) values.
    • For members 6 years or older, submit baseline 6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC). For members younger than 6 years, submit baseline documentation of one or more of upper-airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, and/or 6-MWT.
    Prior Authorization

    Disease and Treatment Background

    Mucopolysaccharidosis VII (MPS VII), also called Sly syndrome, is a rare inherited autosomal recessive lysosomal storage disorder caused by deficient beta-glucuronidase activity. Because glycosaminoglycans are only partially degraded, their fragments accumulate in lysosomes across multiple tissues, eventually causing cellular and organ dysfunction. Clinical presentation and progression vary substantially; manifestations may include cognitive impairment, hepatosplenomegaly, and skeletal dysplasia, with some patients developing early, severe disease and others having later onset with normal or near-normal intelligence.

    Definitions

    Mucopolysaccharidosis VII
    Also known asMPS VII or Sly syndrome
    Disease typeRare autosomal recessive lysosomal storage disorder
    Underlying deficiencyDeficiency of beta-glucuronidase activity
    GUSB deficiency
    EnzymeBeta-glucuronidase, also called GUS or GUSB
    DeficiencyDeficient beta-glucuronidase enzyme activity
    Diagnostic significanceAn enzyme activity assay showing GUSB deficiency confirms MPS VII

    Mepsevii Initial Authorization Criteria

    Mepsevii Initial Authorization

    Initial Mepsevii authorization requires all of the following:

    Mepsevii initial authorization

    • Documented diagnosis of Mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome.
    • Confirmatory diagnosis: Confirmation by enzyme activity assay showing beta-glucuronidase (GUSB) deficiency OR genetic testing showing a mutation of chromosome 7q21.11.

      For newborn or sibling screening, elevated GAGs and two mutations consistent with MPS VII are appropriate; some members may have GAGs elevated only to 2 times the upper limit of normal.

    • Disease manifestation: At least one of the following symptoms consistent with MPS VII: enlarged liver and spleen, joint limitations, airway obstruction, or pulmonary dysfunction.At least 1 symptom

    Mepsevii Continuation Criteria

    Mepsevii Continuation

    Continuation of Mepsevii requires all of the following:

    Mepsevii continuation

    • Positive response or disease stability

      • Decreased urinary GAG: Urinary GAG levels have decreased compared with the pretreatment baseline.
      • Age-appropriate response or stability measure: For members 6 years or older: 6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC); for members younger than 6 years: decreased hepatosplenomegaly, improvement in upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, and/or 6-minute walk test.
    • Tolerability and safety: The prescriber attests to, or the clinical reviewer has found, no evidence of intolerable adverse effects or drug toxicity, including anaphylaxis or severe allergic reactions.

    Quantity and Dosing Limits

    Mepsevii (vestronidase alfa-vjbk)
    Dose4 mg/kg per dose
    FrequencyOnce every 2 weeks (every other week)
    RouteIntravenous infusion

    Administration Site of Care

    Note

    Use an approved infusion site

    Administer infused Mepsevii under the Molina Health Care Site of Care program in a non-hospital facility-based location. The Specialty Medication Administration Site of Care Coverage Criteria applies.

    • Use a non-hospital facility-based place of service for administration.
    • Follow the Molina Health Care Site of Care program requirements.
    • Review the Specialty Medication Administration Site of Care Coverage Criteria for applicable requirements.
    Policy Summary
    PayerMolina Healthcare
    PolicyMepsevii (vestronidase alfa-vjbk) for Mucopolysaccharidosis VII
    Policy CodePolicy C17942-A
    Change TypeAnnual review — no material clinical or coverage changes
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization documentation confirming MPS VII, confirmatory testing, qualifying symptoms, baseline assessments, and qualified specialist prescribing.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersAuthorization and Provider RequirementsDisease and Treatment BackgroundDefinitionsMepsevii Initial Authorization CriteriaMepsevii Continuation CriteriaQuantity and Dosing LimitsAdministration Site of Care
    Baseline assessment for members 6 years or older
    Required assessment6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC)
    Applicable ageMembers 6 years or older
    TimingBaseline, before therapy
    Baseline assessment for members younger than 6 years
    Applicable ageMembers younger than 6 years
    Qualifying assessmentsUpper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, and/or 6-minute walk test
    TimingBaseline, before therapy
    Continuation response for members 6 years or older
    Required laboratory responseDecreased urinary glycosaminoglycan (GAG) levels
    Age 6 years or older6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC) must show response or stability compared with baseline
    Reauthorization basisPositive response or disease stability compared with pretreatment baseline
    Continuation response for members younger than 6 years
    Required laboratory responseDecreased urinary glycosaminoglycan (GAG) levels
    Qualifying response or stability measuresDecreased hepatosplenomegaly, improvement in upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, and/or 6-minute walk test
    Reauthorization basisPositive response or disease stability compared with pretreatment baseline

    Continuation Prior Authorization

    Reauthorization is required every 12 months. Continuation requests must demonstrate positive response or disease stability compared with pretreatment baseline and continued tolerability.

    • Document decreased urinary GAG levels.
    • For members 6 years or older, document improvement or stability by 6-MWT and/or percent predicted FVC.
    • For members younger than 6 years, document decreased hepatosplenomegaly, improvement in upper-airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, and/or 6-MWT.
    • The prescriber must attest, or the clinical reviewer must find, no intolerable adverse effects or drug toxicity, including anaphylaxis or severe allergic reactions.
    Documentation Required

    Required Clinical Documentation

    Provide complete clinical records supporting the diagnosis, medical necessity, and response assessment. Molina may require additional documentation for coverage determination, quality improvement, and fraud, waste, and abuse prevention.

    • Patient records and relevant test results, including diagnostic enzyme activity or genetic testing results.
    • Clinical documentation of qualifying MPS VII symptoms and the applicable baseline and follow-up measurements.
    • Documentation of uGAG results and age-appropriate functional, respiratory, developmental, cardiac, growth, or hepatosplenomegaly assessments.
    • Credentials of the provider ordering or performing the drug or service, when requested.
    Documentation Required

    Specialist Consultation and Supplemental Records

    Mepsevii must be prescribed by, or in consultation with, an appropriately qualified specialist. When prescribed in consultation, submit the consultation documentation with both the initial request and each reauthorization request.

    • Acceptable specialists include a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, physician specializing in lysosomal storage disorders, or physician experienced in managing mucopolysaccharidoses (MPS).
    • Molina may request supplemental patient records, test results, provider credentials, or other documentation needed to evaluate coverage.
    Denial Risk

    Medical-Necessity and Indication Failure Risks

    Mepsevii is covered only when the documented diagnosis, indication, age, clinical findings, baseline requirements, and applicable continuation criteria are met. Other uses are considered experimental or investigational and follow Molina's Off-Label policy.

    • The member must have MPS VII (Sly syndrome), an accepted diagnostic confirmation, and at least one qualifying symptom.
    • The member must be at least 5 months of age and meet the applicable baseline or response/stability requirements.
    • All other uses are experimental/investigational; the policy lists no labeled contraindications, but continuation requires no intolerable adverse effects or drug toxicity.
    • Coverage remains subject to the member's benefit eligibility and benefit document; the guideline does not itself guarantee coverage.
    • Mepsevii carries a Black Box Warning for anaphylaxis. Appropriate medical support must be readily available during administration; closely observe the patient during and for 60 minutes after infusion, and immediately discontinue the infusion if anaphylaxis occurs.
    Denial Risk

    Insufficient Documentation or Improper Billing

    Molina may deny reimbursement or take other appropriate action when submitted records do not support medical necessity, covered status, or the initial determination, or when billing or other practices are inappropriate or excessive.

    • Submit sufficient records, test results, provider credentials, and clinical rationale to support the requested drug or service.
    • Use appropriate industry-standard coding and billing practices. The listed HCPCS code is J3397 for injection, vestronidase alfa-vjbk, 1 mg; code listing does not guarantee coverage.
    • Claims may be rejected or denied, and payments may be recovered, when services are billed improperly or are not a covered benefit.
    • Deleted, inactive, or otherwise inapplicable codes may not be reimbursable, and policy codes may not be all-inclusive or applicable to every state or line of business.
    GAG
    MeaningGlycosaminoglycans
    Disease processGAGs are partially or incompletely degraded and accumulate as fragments in lysosomes
    Clinical useUrinary GAG levels are documented at baseline and used to assess response during continuation therapy
  1. Baseline monitoring

    • Urinary GAG: Documented baseline urinary glycosaminoglycan (uGAG).
    • Age-appropriate functional or disease assessment: For members 6 years or older: 6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC); for members younger than 6 years: upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, and/or 6-minute walk test.
  2. Qualified prescriber: Treatment is prescribed by, or in consultation with, a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, physician specializing in lysosomal storage disorders, or physician experienced in managing mucopolysaccharidoses (MPS).

    If prescribed in consultation, consultation notes must be submitted with the initial request.